ES2697696T3 - Microesferas de liberación sostenida y método de producción de las mismas - Google Patents
Microesferas de liberación sostenida y método de producción de las mismas Download PDFInfo
- Publication number
- ES2697696T3 ES2697696T3 ES14762738T ES14762738T ES2697696T3 ES 2697696 T3 ES2697696 T3 ES 2697696T3 ES 14762738 T ES14762738 T ES 14762738T ES 14762738 T ES14762738 T ES 14762738T ES 2697696 T3 ES2697696 T3 ES 2697696T3
- Authority
- ES
- Spain
- Prior art keywords
- dispersed phase
- active ingredient
- betamethasone
- filtering
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 56
- 238000013268 sustained release Methods 0.000 title claims abstract description 15
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 48
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims abstract description 40
- 229960002537 betamethasone Drugs 0.000 claims abstract description 40
- 238000009472 formulation Methods 0.000 claims abstract description 34
- 229920000642 polymer Polymers 0.000 claims abstract description 32
- 238000001914 filtration Methods 0.000 claims abstract description 28
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 239000002904 solvent Substances 0.000 claims abstract description 19
- 239000004615 ingredient Substances 0.000 claims abstract description 17
- 230000000975 bioactive effect Effects 0.000 claims abstract description 16
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 16
- 229920000747 poly(lactic acid) Polymers 0.000 claims abstract description 14
- 230000001954 sterilising effect Effects 0.000 claims abstract description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 22
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 21
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 2
- 238000004388 gamma ray sterilization Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 27
- 239000003814 drug Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- 239000002033 PVDF binder Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000009826 distribution Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000006069 physical mixture Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000020550 Joint related disease Diseases 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 229920006125 amorphous polymer Polymers 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790554P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/028657 WO2014144309A1 (en) | 2013-03-15 | 2014-03-14 | Sustained release microspheres and method of producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2697696T3 true ES2697696T3 (es) | 2019-01-25 |
Family
ID=51537672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14762738T Active ES2697696T3 (es) | 2013-03-15 | 2014-03-14 | Microesferas de liberación sostenida y método de producción de las mismas |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9956177B2 (https=) |
| EP (1) | EP2968184B1 (https=) |
| JP (2) | JP2016515517A (https=) |
| CN (1) | CN105705141B (https=) |
| CA (1) | CA2909303C (https=) |
| ES (1) | ES2697696T3 (https=) |
| MX (1) | MX362187B (https=) |
| WO (1) | WO2014144309A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9956177B2 (en) | 2013-03-15 | 2018-05-01 | Oakwood Laboratories LLC | Sustained release microspheres and method of producing same |
| CN113766952B (zh) * | 2019-03-29 | 2023-09-08 | 国立研究开发法人量子科学技术研究开发机构 | 放射性药品的制造方法及放射性药品 |
| JP2023551508A (ja) * | 2020-11-30 | 2023-12-08 | エルジー・ケム・リミテッド | カスパーゼ阻害剤を含有する注射用組成物及びその製造方法 |
| US11992559B2 (en) | 2021-02-24 | 2024-05-28 | Oakwood Laboratories, Llc | Microsphere formulations comprising lurasidone and methods for making and using the same |
| US20240148662A1 (en) * | 2021-03-11 | 2024-05-09 | Oakwood Laboratories, Llc | Methods and systems for making polymer microspheres |
| CN116999412A (zh) * | 2023-08-03 | 2023-11-07 | 四川迈可隆生物科技有限公司 | 一种含有倍他米松药物的缓释微球制剂及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5945125A (en) | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
| US6046187A (en) * | 1996-09-16 | 2000-04-04 | Children's Medical Center Corporation | Formulations and methods for providing prolonged local anesthesia |
| SE9704186D0 (sv) * | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
| US6270802B1 (en) | 1998-10-28 | 2001-08-07 | Oakwood Laboratories L.L.C. | Method and apparatus for formulating microspheres and microcapsules |
| WO2002078673A1 (fr) * | 2001-03-29 | 2002-10-10 | Takeda Chemical Industries, Ltd. | Procede de production d'un medicament sous forme de granules fins |
| JP2002356419A (ja) * | 2001-03-29 | 2002-12-13 | Takeda Chem Ind Ltd | 微粒薬物の製造法 |
| WO2005107714A2 (en) * | 2004-05-05 | 2005-11-17 | Alkermes Controlled Therapeutics, Inc. | Method of forming microparticles that include a bisphosphonate and a polymer |
| GB2459910B (en) | 2008-04-21 | 2010-03-31 | Otonomy Inc | Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders |
| US20100086596A1 (en) * | 2008-10-06 | 2010-04-08 | Oakwood Laboratories LLC | Microspheres for releasing an octreotide compound without an initial time lag |
| US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| UA111162C2 (uk) * | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
| US8708159B2 (en) * | 2011-02-16 | 2014-04-29 | Oakwood Laboratories, Llc | Manufacture of microspheres using a hydrocyclone |
| US9956177B2 (en) | 2013-03-15 | 2018-05-01 | Oakwood Laboratories LLC | Sustained release microspheres and method of producing same |
-
2014
- 2014-03-14 US US14/774,851 patent/US9956177B2/en active Active
- 2014-03-14 EP EP14762738.4A patent/EP2968184B1/en active Active
- 2014-03-14 WO PCT/US2014/028657 patent/WO2014144309A1/en not_active Ceased
- 2014-03-14 CN CN201480016260.6A patent/CN105705141B/zh active Active
- 2014-03-14 JP JP2016502862A patent/JP2016515517A/ja active Pending
- 2014-03-14 ES ES14762738T patent/ES2697696T3/es active Active
- 2014-03-14 MX MX2015012231A patent/MX362187B/es active IP Right Grant
- 2014-03-14 CA CA2909303A patent/CA2909303C/en active Active
-
2019
- 2019-04-19 JP JP2019080106A patent/JP6808777B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2909303C (en) | 2021-10-19 |
| MX2015012231A (es) | 2016-05-05 |
| MX362187B (es) | 2019-01-08 |
| JP2016515517A (ja) | 2016-05-30 |
| EP2968184B1 (en) | 2018-10-24 |
| US20160030351A1 (en) | 2016-02-04 |
| JP6808777B2 (ja) | 2021-01-06 |
| BR112015022524A2 (pt) | 2017-08-22 |
| JP2019112471A (ja) | 2019-07-11 |
| WO2014144309A1 (en) | 2014-09-18 |
| CN105705141A (zh) | 2016-06-22 |
| EP2968184A4 (en) | 2016-09-07 |
| CA2909303A1 (en) | 2014-09-18 |
| CN105705141B (zh) | 2018-12-28 |
| EP2968184A1 (en) | 2016-01-20 |
| US9956177B2 (en) | 2018-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2697696T3 (es) | Microesferas de liberación sostenida y método de producción de las mismas | |
| ES2717942T3 (es) | Microesferas de buprenorfina de alta carga de fármaco y método de producción de las mismas | |
| EP2644191B1 (en) | Nonwoven membrane as a drug delivery system | |
| Lim et al. | One-step fabrication of core–shell structured alginate–PLGA/PLLA microparticles as a novel drug delivery system for water soluble drugs | |
| US12220427B2 (en) | Continuous release compositions made from hyaluronic acid, and therapeutic applications of same | |
| Zhang et al. | Polymeric non-spherical coarse microparticles fabricated by double emulsion-solvent evaporation for simvastatin delivery | |
| Solano et al. | Development and evaluation of sustained-release etoposide-loaded poly (ε-caprolactone) implants | |
| KR102493997B1 (ko) | 센텔라아시아티카를 함유한 용해성 마이크로니들 패치 | |
| Kaur et al. | Polymer based microspheres of aceclofenac as sustained release parenterals for prolonged anti-inflammatory effect | |
| KR102427305B1 (ko) | 국소 투여용 이중 봉입 생분해성 고분자 미립구의 제조방법 및 이를 포함하는 주사제 | |
| Tiwari et al. | A review on use of novel drug delivery systems in herbal medicines | |
| KR20210054660A (ko) | 초기 방출 제어가 가능한 서방출성 미립구 및 이의 제조 방법 | |
| US9636308B2 (en) | High drug load buprenorphine microspheres and method of producing same | |
| JP2016515517A5 (https=) | ||
| ES2947659T3 (es) | Método de procesamiento para biopolímeros usando combinaciones de solventes | |
| JP2023538901A (ja) | ケタミンを含むマイクロスフェア製剤ならびにその製造及び使用方法 | |
| CN103690512B (zh) | 一种去氧鬼臼毒素聚合物胶束冻干制剂 | |
| Wang et al. | Molecularly engineered controlled release systems for local anesthetics in precise pain management | |
| CN112367997A (zh) | 一种叔胺药物组合物及其产业化批量制备方法 | |
| BR112015022524B1 (pt) | Método de produção de uma formulação de microesferas de liberação sustentada e formulação de liberação sustentada | |
| CN1444948B (zh) | 灯盏花素脂质体及其制备方法 | |
| Zhang | Biodegradable microparticles and in situ forming implants/microparticles containing drugs in different physical states | |
| Gignone | Ordered Mesoporous Silica for Drug Delivery in Topical Applications | |
| Chakraborty et al. | Silk fibroin: A smart biomaterial for long term and targeted nanotherapeutics |